| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human,Mouse,Rat |
| Host species | Rabbit |
| Applications | ELISA,WB-Ce |
| Brand: | Abnova |
| Reference: | PAB7918 |
| Product name: | ABL1 (phospho Y245) polyclonal antibody |
| Product description: | Rabbit polyclonal antibody raised against synthetic phosphopeptide of ABL1. |
| Gene id: | 25 |
| Gene name: | ABL1 |
| Gene alias: | ABL|JTK7|bcr/abl|c-ABL|p150|v-abl |
| Gene description: | c-abl oncogene 1, receptor tyrosine kinase |
| Immunogen: | Synthetic phosphopeptide (conjugated with KLH) corresponding to residues surrounding Y245 of human ABL1. |
| Form: | Liquid |
| Recommend dilutions: | ELISA (1:2000) Western Blot (1:1000) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS (50% glycerol, 1 mg/mL BSA, 0.05% sodium azide) |
| Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Rabbit |
| Antigen species / target species: | Human |
| Specificity: | This peptide sequence has high homology to the conserved site in rat and mouse c-Abl, as well as in viral Abl and BCR-Abl fusion protein. |
| Reactivity: | Human,Mouse,Rat |
| Application image: | ![]() |
| Application image note: | Western blot analysis of K-562 cells treated with pervanadate (1 mM) for 30 minutes (lanes 1 & 3). Some lanes were treated with alkaline phosphatase to remove phosphorylation on ABL1 (lanes 2 & 4), then the blots were probed with anti ABL1 (lanes 1 & 2), ABL1 (phospho Y245) polyclonal antibody (Cat # PAB7918) (lanes 3 & 4). |
| Applications: | ELISA,WB-Ce |
| Shipping condition: | Dry Ice |
| Publications: | Cycling, stressed-out and nervous: cellular functions of c-Abl.Van Etten RA. Trends Cell Biol. 1999 May;9(5):179-86. |